Posted by Michael Wonder on 02 May 2017
Sanofi Genzyme announces approval of Cerdelga (eliglustat tartrate) by Health Canada for rare genetic condition
1 May 2017 - Sanofi Genzyme announced today that Health Canada has recently approved Cerdelga (eliglustat capsules), the only first-line oral therapy indicated for the treatment of adult patients with Gaucher Disease Type 1.
A rare genetic metabolic condition that causes fats to build up in certain parts of the body, Gaucher Disease Type 1 is progressive and may become life-threatening if symptoms are left untreated. Patients who are specific enzyme metabolisers, as detected by a simple test, will be eligible for Cerdelga treatment.
